ChrXq27.3 miRNA cluster functions in cancer development.
Drug-resistance
Epithelial–mesenchymal transition
Proliferation
X chromosome
miR-506-3p
miR-888-5p
miRNA
miRNA cluster
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
25 Mar 2021
25 Mar 2021
Historique:
received:
02
02
2021
accepted:
14
03
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
3
11
2021
Statut:
epublish
Résumé
MicroRNAs (miRNAs) regulate the expression of their target genes post-transcriptionally; thus, they are deeply involved in fundamental biological processes. miRNA clusters contain two or more miRNA-encoding genes, and these miRNAs are usually coexpressed due to common expression mechanisms. Therefore, miRNA clusters are effective modulators of biological pathways by the members coordinately regulating their multiple target genes, and an miRNA cluster located on the X chromosome q27.3 region has received much attention in cancer research recently. In this review, we discuss the novel findings of the chrXq27.3 miRNA cluster in various types of cancer.The chrXq27.3 miRNA cluster contains 30 mature miRNAs synthesized from 22 miRNA-encoding genes in an ~ 1.3-Mb region. The expressions of these miRNAs are usually negligible in many normal tissues, with the male reproductive system being an exception. In cancer tissues, each miRNA is dysregulated, compared with in adjacent normal tissues. The miRNA-encoding genes are not uniformly distributed in the region, and they are further divided into two groups (the miR-506-514 and miR-888-892 groups) according to their location on the genome. Most of the miRNAs in the former group are tumor-suppressive miRNAs that are further downregulated in various cancers compared with normal tissues. miR-506-3p in particular is the most well-known miRNA in this cluster, and it has various tumor-suppressive functions associated with the epithelial-mesenchymal transition, proliferation, and drug resistance. Moreover, other miRNAs, such as miR-508-3p and miR-509-3p, have similar tumor-suppressive effects. Hence, the expression of these miRNAs is clinically favorable as prognostic factors in various cancers. However, the functions of the latter group are less understood. In the latter group, miR-888-5p displays oncogenic functions, whereas miR-892b is tumor suppressive. Therefore, the functions of the miR-888-892 group are considered to be cell type- or tissue-specific.In conclusion, the chrXq27.3 miRNA cluster is a critical regulator of cancer progression, and the miRNAs themselves, their regulatory mechanisms, and their target genes might be promising therapeutic targets.
Identifiants
pubmed: 33766100
doi: 10.1186/s13046-021-01910-0
pii: 10.1186/s13046-021-01910-0
pmc: PMC7992321
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20ck0106630h0001
Organisme : Yokohama Foundation for Clinical Pharmacology
ID : TRY-2014
Références
Onco Targets Ther. 2019 Dec 02;12:10515-10522
pubmed: 31819532
Oncogene. 2014 Jun 19;33(25):3267-76
pubmed: 23893241
Mol Cells. 2014 Apr;37(4):314-21
pubmed: 24802056
Am J Transl Res. 2017 Dec 15;9(12):5332-5346
pubmed: 29312487
Nucleic Acids Res. 2009 May;37(8):2419-33
pubmed: 19295136
Am J Pathol. 2015 Sep;185(9):2412-20
pubmed: 26362716
Arch Gynecol Obstet. 2017 Sep;296(3):543-549
pubmed: 28660502
J Neurodev Disord. 2020 May 2;12(1):13
pubmed: 32359368
J Cell Biochem. 2017 Jun;118(6):1489-1496
pubmed: 27883251
Theranostics. 2019 Oct 21;9(26):8294-8311
pubmed: 31754397
Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3617-3625
pubmed: 28925482
Oncotarget. 2016 Dec 13;7(50):82338-82353
pubmed: 27494897
Biomed Pharmacother. 2015 May;72:119-24
pubmed: 26054685
Cancer Cell. 2013 Feb 11;23(2):186-99
pubmed: 23410973
Bioessays. 2011 Nov;33(11):791-802
pubmed: 21953569
Cancer Biol Ther. 2019;20(6):826-836
pubmed: 30907227
J Cell Physiol. 2019 Jul;234(7):10934-10941
pubmed: 30623409
J Exp Clin Cancer Res. 2019 Feb 21;38(1):97
pubmed: 30791932
Oncogene. 2015 Sep 10;34(37):4890-900
pubmed: 25659578
Biochem Biophys Res Commun. 2015 Nov 27;467(4):921-7
pubmed: 26474697
Biochem Biophys Res Commun. 2016 Sep 16;478(2):676-82
pubmed: 27498003
Aging (Albany NY). 2020 Oct 20;12(20):20645-20657
pubmed: 33082297
Oncogene. 2021 Feb;40(7):1255-1268
pubmed: 33420363
J Pathol. 2015 Jan;235(1):25-36
pubmed: 25230372
Front Cell Dev Biol. 2019 Nov 15;7:266
pubmed: 31803739
PLoS One. 2015 Mar 20;10(3):e0120258
pubmed: 25793370
Mol Med Rep. 2017 Aug;16(2):2163-2171
pubmed: 28627698
Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6379-6385
pubmed: 30338806
Oncogene. 2019 Mar;38(13):2305-2319
pubmed: 30478449
Nucleic Acids Res. 2015 Apr 30;43(8):4075-86
pubmed: 25845598
Oncol Res. 2017 Mar 13;25(3):455-461
pubmed: 27697095
J Cell Biochem. 2018 Jul;119(7):6045-6056
pubmed: 29574975
Mol Cell Biochem. 2020 Jan;463(1-2):127-136
pubmed: 31595421
Mol Cancer Res. 2014 Jan;12(1):58-68
pubmed: 24307696
Nature. 2005 Jun 9;435(7043):828-33
pubmed: 15944707
Cell Death Dis. 2018 Jun 7;9(6):687
pubmed: 29880874
Cancer Res. 2016 Mar 1;76(5):1101-11
pubmed: 26747895
Am J Cancer Res. 2018 Aug 01;8(8):1586-1594
pubmed: 30210926
J Natl Cancer Inst. 2015 May 20;107(7):
pubmed: 25995442
Neoplasma. 2018 Mar 14;65(3):331-338
pubmed: 29788724
Oncol Rep. 2016 Oct;36(4):2313-20
pubmed: 27573859
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Onco Targets Ther. 2016 Dec 19;10:35-46
pubmed: 28031721
Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2020-2027
pubmed: 30915745
EMBO Rep. 2019 Feb;20(2):
pubmed: 30573526
Oncol Lett. 2019 Jan;17(1):73-78
pubmed: 30655740
Aging (Albany NY). 2019 Mar 6;11(5):1471-1485
pubmed: 30840927
Theranostics. 2020 Mar 15;10(10):4395-4409
pubmed: 32292503
Carcinogenesis. 2018 Feb 9;39(2):98-108
pubmed: 29126102
Arch Med Sci. 2019 Jul;15(4):968-978
pubmed: 31360191
Neoplasma. 2017;64(1):40-47
pubmed: 27881003
J Cancer. 2019 Jun 9;10(15):3560-3570
pubmed: 31293661
PLoS One. 2015 Apr 09;10(4):e0122851
pubmed: 25856555
Cancer Cell Int. 2018 Oct 25;18:171
pubmed: 30386180
Oncogene. 2019 Mar;38(12):2042-2055
pubmed: 30401982
Iran J Basic Med Sci. 2016 Mar;19(3):316-22
pubmed: 27114802
Mol Cancer Res. 2018 Apr;16(4):669-681
pubmed: 29330297
BMC Cancer. 2019 Jun 13;19(1):577
pubmed: 31196010
Oncotarget. 2017 Jan 3;8(1):644-657
pubmed: 27893417
J Genet Genomics. 2014 Jan 20;41(1):35-42
pubmed: 24480745
Transl Oncol. 2015 Apr;8(2):85-96
pubmed: 25926074
Cell Death Dis. 2018 Aug 28;9(9):861
pubmed: 30154460
Tumour Biol. 2014 Nov;35(11):11081-9
pubmed: 25095979
Int J Stem Cells. 2019 Jul 31;12(2):347-359
pubmed: 31242722
J Pathol. 2014 Jul;233(3):308-18
pubmed: 24604117
Oncol Rep. 2020 Oct;44(4):1403-1414
pubmed: 32945466
Oncogene. 2015 Feb 5;34(6):717-25
pubmed: 24608427
Oncogene. 2015 Feb 5;34(6):691-703
pubmed: 24469051
Mol Cancer. 2016 Jan 22;15:9
pubmed: 26801246
Genome Res. 2007 May;17(5):612-7
pubmed: 17416744
Oncol Lett. 2018 Jun;15(6):9101-9109
pubmed: 29928331
J Cell Biochem. 2019 Feb 20;:
pubmed: 30790329
Oncogenesis. 2019 Oct 23;8(11):62
pubmed: 31645542
J Cell Biochem. 2018 Sep;119(9):7431-7440
pubmed: 29781537
Open Med (Wars). 2020 Sep 30;15(1):921-931
pubmed: 33336050
Biochem Biophys Res Commun. 2012 Mar 23;419(4):621-6
pubmed: 22369946
PLoS One. 2013 May 22;8(5):e64273
pubmed: 23717581
Onco Targets Ther. 2017 Sep 11;10:4455-4464
pubmed: 28979137
Nat Commun. 2014 Aug 06;5:4620
pubmed: 25099196
Cancer Res. 2005 Nov 1;65(21):9628-32
pubmed: 16266980
Oncol Rep. 2016 May;35(5):3106-14
pubmed: 26935526
Oncogene. 2016 Oct 20;35(42):5501-5514
pubmed: 27065335
Oncotarget. 2011 Dec;2(12):1265-78
pubmed: 22246208
Oncol Res. 2019 Aug 8;27(8):879-887
pubmed: 30982489
Am J Transl Res. 2018 Feb 15;10(2):592-604
pubmed: 29511454
Cancer Res. 2018 Apr 1;78(7):1751-1765
pubmed: 29374066
J Cell Mol Med. 2020 Jan;24(2):1437-1450
pubmed: 31851778
Life Sci. 2019 Oct 1;234:116789
pubmed: 31454494
Wiley Interdiscip Rev RNA. 2020 Mar;11(2):e1563
pubmed: 31436881
J Hematol Oncol. 2020 Jan 31;13(1):9
pubmed: 32005272
Sci Rep. 2017 Jun 21;7(1):4002
pubmed: 28638102
Oncotarget. 2016 Jun 14;7(24):36743-36754
pubmed: 27167339
Mol Biol Evol. 2010 Mar;27(3):671-83
pubmed: 19933172
J Cell Biochem. 2019 Mar;120(3):3780-3789
pubmed: 30382592
Cell Death Dis. 2014 Aug 21;5:e1387
pubmed: 25144722
Aging (Albany NY). 2019 Mar 28;11(6):1821-1831
pubmed: 30923258
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9955-9964
pubmed: 31799665
Pharmacogenomics. 2016 Feb;17(3):187-97
pubmed: 26786897
Sci Rep. 2018 Jul 12;8(1):10495
pubmed: 30002440
Am J Cancer Res. 2015 Aug 15;5(9):2697-707
pubmed: 26609477
Cell Physiol Biochem. 2016;38(4):1435-46
pubmed: 27035590
Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5133-5138
pubmed: 31298366
Biochem Biophys Res Commun. 2017 Jan 22;482(4):828-834
pubmed: 27888106
Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2856-2862
pubmed: 31002136
Lancet Oncol. 2017 Oct;18(10):1386-1396
pubmed: 28870611
Breast Cancer Res. 2013;15(4):R70
pubmed: 23971998